ABCL575 / AbCellera - LARVOL DELTA

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting (Businesswire) - "AbCellera’s presentation...describes key properties of ABCL575, including: (i) Potent functional activity that is equivalent to the most advanced clinical benchmark, with inhibition of OX40L signalling and T-cell activation in vitro and significant reduction of Th2 cytokines in vivo; (ii) Modified Fc domain that supports Fc-silencing and half-life extension, with a predicted human half-life of more than 60 days from preclinical in vivo PK data; (iii) Positive nonclinical safety profile and favorable stability when formulated at high concentration....'We look forward to advancing this molecule into the clinic and are on track to do so this year'."

New trial • Preclinical • Atopic Dermatitis

AbCellera Reports Full Year 2024 Business Results (Businesswire) - "'We also maintained our strong cash position, closing the year with over $800 million in available liquidity to execute on our strategy,'...As a result, we enter 2025 on track to initiate Phase 1 clinical trials for our first two programs, ABCL635 and ABCL575, and to start activities in our new clinical manufacturing facility.'...Revenue – Total revenue was $28.8 million, compared to $38.0 million in 2023. In both periods, the majority of revenues were research fees generated by our partnerships."

Commercial • New P1 trial • Immunology • Metabolic Disorders

AbCellera Reports Q2 2024 Business Results (Businesswire) - "Q2 2024 Business Summary: ABCL635 and ABCL575 remain on track for anticipated Clinical Trial Applications (CTAs) in the second quarter of 2025."

New trial • Atopic Dermatitis